MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
18.47
+0.21
+1.15%
After Hours: 17.89 -0.58 -3.14% 19:05 05/07 EDT
OPEN
22.55
PREV CLOSE
18.26
HIGH
25.42
LOW
18.00
VOLUME
711.34K
TURNOVER
--
52 WEEK HIGH
29.82
52 WEEK LOW
7.48
MARKET CAP
330.00M
P/E (TTM)
18.68
1D
5D
1M
3M
1Y
5Y
1D
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Dow Jones · 10h ago
Rigel Pharmaceuticals Price Target Raised to $23.00/Share From $20.00 by Cantor Fitzgerald
Dow Jones · 10h ago
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday
Benzinga · 10h ago
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23
Benzinga · 11h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12h ago
Rigel’s Strong Q1 Performance and Strategic Focus Bolster Buy Rating
TipRanks · 14h ago
Rigel Pharmaceuticals Reports Strong Q1 2025 Earnings
TipRanks · 20h ago
Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance
Seeking Alpha · 21h ago
More
About RIGL
More
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Recently
Symbol
Price
%Change

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.